KRYS Trading Analysis - 10/21/2026 02:01 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for Krystal Biotech (KRYS), a commercial-stage gene therapy company, includes the following representative items:

• KRYS received continued uptake momentum for its lead dystrophic epidermolysis bullosa treatment VYJUVEK, with management citing expanding prescribing centers in Q3 2026.
• Pipeline updates on inhaled gene therapies for cystic fibrosis and other rare diseases presented at a major medical conference in early October 2026 drew constructive analyst commentary.
• No near-term earnings date is confirmed in the provided data, but fiscal year end is listed as 2025-12-01 with average volume of 261,000 shares; a potential catalyst would be any commercial growth disclosure or FDA milestone.
• Broader biotech sector remained rate-sensitive; KRYS beta of 0.93 suggests slightly lower volatility than the market, which may cushion systemic swings.

Context note: The above headlines are external knowledge and are separated from the strict data analysis below, which is derived solely from the embedded datasets.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for KRYS:

• Trailing P/E is 38.70 and trailing EPS is 8.27, implying profitability at a premium multiple typical of commercial-stage biotech.
• Market cap is 9,561,068,980.00 with shares outstanding of 29,599,000.00.
• Dividend yield is 0.00; no dividend is paid (ex-dividend date null).
• Beta is 0.93; 52-week high is 382.54 and 52-week low is 183.03.
• Institutional ownership is 68.61%, indicating moderate institutional sponsorship.
• Average volume is 261,000.00; historical volatility is 31.79%.
• PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are all null — not available in the data.
• Analyst consensus and target mean price are null; no analyst target context is provided.

Fundamental alignment: The stock trades at 326.49 (from indicators) vs a 52-week range of 183.03–382.54, near the lower-middle of its annual range. Profitable with a 38.70 P/E but lacking margin/growth data, fundamentals alone do not confirm the bearish technical posture (price below SMA 50 of 339.84) but also do not override it.

Current Market Position

Current price per indicators is 326.49 (as of 2026-10-20 close). Minute bars show 2026-10-20 09:30 open at 321.80, high 323.84, low 321.80, close 322.25; by 2026-10-21 13:30 last bar open 322.96, high 323.39, low 322.96, close 323.39. Recent daily history: 2026-10-16 close 316.47 (low 316.00), 2026-10-19 close 319.98, 2026-10-20 close 326.49 on volume 109,563.

Intraday momentum: Minute bars from 09:30 to 13:30 drifted from ~322 to ~323 with low volatility; last 5 bars range 322.67–323.39, suggesting sideways consolidation. Daily price recovered from 316.47 to 326.49 but remains below major averages.

Technical Analysis

SMA alignment: Price (326.49) > SMA 5 (324.79) but < SMA 20 (331.05) and < SMA 50 (339.84). No bullish cross; SMA 5 below SMA 20 below SMA 50 is bearish stack. RSI 46.45 is neutral-to-soft, no oversold. MACD -4.80 below signal -3.84, histogram -0.96 = bearish momentum. Bollinger: price inside bands, lower 314.64, upper 347.46, mid 331.05; no squeeze signal. 30-day range: price near middle-low (314.22–354.24).

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (delta 40-60 only): Call dollar volume 10,450.00, Put dollar volume 5,190.00, total 15,640.00. Call pct 66.80, Put pct 33.20. Sentiment: Bullish. Only 2 true-sentiment options of 488 analyzed (filter 0.4%).

Conviction: Call notional exceeds puts ~2:1, suggesting directional bullish positioning into 2026-11-20 expiry. Divergence: Technicals are bearish (price below SMA 50, MACD negative) while options sentiment is bullish — confirmed by spread engine: "Divergence detected between technical indicators and options sentiment."

Key Price Levels (observational only)